Related Experiment Video

Updated: Apr 5, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.3K

Genetic Association Studies Reporting on Variants in the C-Reactive Protein Gene and Coronary Artery Disease: A

Yujie Shi1, Jian Zhang, Chen Tan

  • 1From the Cardiovascular Diseases Institute, General Hospital of Beijing Military Command of PLA, Beijing, China.

Medicine
|August 13, 2015
PubMed

Insights

This meta-analysis found no significant association between C-reactive protein (CRP) gene variants (+942G>C, +1444C>T) and coronary artery disease (CAD) risk. A borderline association was noted for the -717A>G variant, suggesting CRP gene variations may not significantly impact CAD risk.

Area of Science:

  • Genetics
  • Cardiovascular Medicine
  • Molecular Biology

Background:

  • C-reactive protein (CRP) is a key inflammatory marker linked to increased coronary artery disease (CAD) risk.
  • Genetic variations in the CRP gene are hypothesized to influence CRP levels and CAD susceptibility.
  • Previous studies on CRP variants and CAD risk have yielded inconsistent results.

Purpose of the Study:

  • To conduct a meta-analysis investigating the association between specific CRP gene variants (+942G>C, -717A>G, +1444C>T) and the genetic risk of coronary artery disease (CAD).

Main Methods:

  • Systematic literature search and meta-analysis of human case-control studies.
  • Inclusion of 16 studies examining CRP variants (+942G>C, -717A>G, +1444C>T) and CAD risk.
  • Application of both random-effect and fixed-effect models to calculate odds ratios (OR) for CAD risk.

Main Results:

  • The CRP +942G>C variant showed no significant association with CAD risk in the overall pooled analysis or subgroup analyses.
  • The CRP +1444C>T variant also demonstrated no significant association with CAD risk.
  • A borderline association between the CRP -717A>G variant and CAD risk was observed under homozygous (OR=0.53) and recessive (OR=0.51) models.

Conclusions:

  • The CRP gene variants examined, including +942G>C and +1444C>T, do not appear to significantly modulate the risk of coronary artery disease.
  • The -717A>G CRP variant exhibited a borderline association with CAD risk, warranting further investigation.
  • Overall, the findings suggest that common CRP gene variations may play a limited role in the genetic predisposition to CAD.

More Related Videos

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.8K
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.6K

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.7K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
86
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
770
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
114
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.7K
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
98